Lyell Immunopharma Q1 revenue misses, adjusted net loss narrows

Lyell Immunopharma

06/05/2026 21:51

Overview

US CAR T-cell therapy developer's Q1 revenue missed analyst expectations

Adjusted net loss for Q1 narrows compared to last year

Company closed $50 mln private placement tranche, ending Q1 with $261 mln in cash

Outlook

Lyell expects cash runway to last into Q3 2027

Result Drivers

ASSET GAIN - Net loss narrowed mainly due to $17.6 mln gain on Securities Purchase Agreement put/call asset from July 2025 equity private placement

LOWER PERSONNEL EXPENSES - Decreased R&D and G&A costs driven by reduced headcount and personnel-related expenses after technology transfer of ronde-cel to LyFE Manufacturing Center

INCREASED CLINICAL TRIAL ACTIVITY - Higher clinical trial and outside services spending partially offset R&D cost reductions

Company press release: ID:nGNX7rhhcK

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$2,000
$4,400 (5 Analysts)
Q1 Adjusted Net Loss
$37.80 mln
Q1 Net Loss
$24.15 mln
Q1 Operating Expenses
$44.26 mln
Q1 Loss from operations
$44.26 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lyell Immunopharma Inc is $44.00, about 113.4% above its May 5 closing price of $20.62

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)